Shamini Selvarajah
Overview
Explore the profile of Shamini Selvarajah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu Y, Selvarajah S, Pal P, Waddell T
Virchows Arch
. 2025 Jan;
PMID: 39751663
The family of PEComa encompasses a heterogeneous group of related mesenchymal neoplasms with myomelanocytic differentiation, a distinctive subset of which is characterized by TFE3 gene rearrangement. Recurrent YAP1::TFE3 fusion has...
2.
Breadner D, Hwang D, Husereau D, Cheema P, Doucette S, Ellis P, et al.
Curr Oncol
. 2024 Oct;
31(10):6017-6031.
PMID: 39451753
Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely access to comprehensive molecular profiling is critical...
3.
Prendeville S, Kaur H, Ansari S, Al Qaqa S, Stockley T, Lajkosz K, et al.
Mod Pathol
. 2024 Apr;
37(6):100489.
PMID: 38588883
Somatic tumor testing in prostate cancer (PCa) can guide treatment options by identifying clinically actionable variants in DNA damage repair genes, including acquired variants not detected using germline testing alone....
4.
Rendon R, Selvarajah S, Wyatt A, Kolinsky M, Schrader K, Fleshner N, et al.
Can Urol Assoc J
. 2023 Oct;
17(10):314-325.
PMID: 37851913
No abstract available.
5.
Schenkel L, Meybodi A, Selvarajah S
Front Oncol
. 2023 Aug;
13:1253630.
PMID: 37637059
No abstract available.
6.
Yip S, Morash C, Kolinsky M, Kapoor A, Ong M, Selvarajah S, et al.
Can Urol Assoc J
. 2023 Jul;
17(10):326-336.
PMID: 37494316
Introduction: In patients with prostate cancer (PCa), the identification of an alteration in genes associated with homologous recombination repair (HRR) has implications for prognostication, optimization of therapy, and familial risk...
7.
Bell K, Kim R, Aronson M, Gillies B, Awan A, Chun K, et al.
J Med Genet
. 2022 Dec;
60(8):769-775.
PMID: 36564171
Background: Genetic testing for hereditary cancer susceptibility has advanced over time due to the discovery of new risk genes, improved technology and decreased cost. In the province of Ontario, testing...
8.
Selvarajah S, Schrader K, Kolinsky M, Rendon R, El Hallani S, Fleshner N, et al.
Can Urol Assoc J
. 2022 Oct;
16(10):321-332.
PMID: 36240332
Introduction: Genetic testing in advanced prostate cancer is rapidly moving to become standard of care. Testing for genetic alterations in genes involved in DNA repair pathways, particularly those implicated in...
9.
Peng J, Sridhar S, Siefker-Radtke A, Selvarajah S, Jiang D
Curr Treat Options Oncol
. 2022 Aug;
23(9):1269-1287.
PMID: 35962938
As we come to better understand cancer genomics, we are increasingly shifting towards precision medicine. FGFR has been elucidated as one of the oncogenic driver pathways in urothelial carcinoma, leading...
10.
Kappel C, Jiang D, Wong B, Zhang T, Selvarajah S, Warner E, et al.
Clin Genitourin Cancer
. 2022 Mar;
20(3):278-284.
PMID: 35337750
Introduction: While comprehensive genomic profiling (CGP) data is becoming increasingly important in the management of prostate cancer, it remains under-utilized in the setting of metastatic castrate sensitive prostate cancer (mCSPC)....